Actionable news
0
All posts from Actionable news
Actionable news in CGIX: Cancer Genetics, Inc.,

Cancer Genetics, Inc. Strengthens Position as a Leader in Myeloid Cancer Diagnosis and Management Receiving New York State Approval for Focus::Myeloid™, a Targeted NGS Panel for Improved Diagnosis, Risk Stratification, and Therapy Selection of Patients with Myeloid Cancers

  • Focus::Myeloid™ can help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently living with myeloid malignancies

  • Focus::Myeloid™ is a targeted NGS panel for myeloid malignancies with 54 genes designed to provide actionable information for clinical management of patients and for use in clinical trials

RUTHERFORD, N.J., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it received New York State approval for its Focus::Myeloid™ NGS-based panel for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).

“This New York State approval is another tribute to CGI’s ability to provide NGS panels that meet the highest quality standards and improve patient care. Focus::Myeloid™ is a highly sophisticated panel designed by a consortium of recognized experts in hematological malignancies. CGI will tailor the report output to provide test results for specific myeloid cancer indications, including AML, MDS, and MPN,” said CGI President and CEO, Panna Sharma.

Focus::Myeloid™ is a unique NGS panel with 54 genes providing actionable information for improved diagnosis, prognosis, therapy selection, and risk stratification of myeloid cancer patients. Based on the result of the test, each patient can receive the most suitable treatment tailored to their unique myeloid cancer. In addition to being available as an individual test, Focus::Myeloid™ is integrated into the company’s Complete™ programs for AML, MDS, and MPN, which offer a comprehensive assessment of the...


More